Information Provided By:
Fly News Breaks for December 12, 2016
IART, MDXG
Dec 12, 2016 | 05:52 EDT
UBS analyst Matt Miksic started MiMedx Group with a Sell rating and $9 price target. The analyst says his firm's survey of 100 U.S. wound care specialists suggests Integra LifeSciences' (IART) Omnigraft launch will put competitive pressure on MiMedx's EpiFix over time. The stock at current levels is not discounting significant market share losses or decelerating growth, Miksic tells investors in a research note.
News For MDXG;IART From the Last 2 Days
There are no results for your query MDXG;IART
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.